Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: a prospective cohort study and analysis of transcriptomic predictors of response

Drennan P. et al, (2024), Lancet microbe

Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial

Harris V. et al, (2024), The lancet infectious diseases

Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.

Hobbs FR. et al, (2024), J infect

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2.

Higham HE. et al, (2024), Br j clin pharmacol, 90, 1586 - 1599

PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations (the PERISCOPE trial) - a study protocol for a pragmatic, UK multicentre, superiority randomised controlled trial with an internal pilot, economic evaluation and nested qualitative study.

Brady S. et al, (2024), Bmj open, 14

PERI-operative biologic DMARD management: Stoppage or COntinuation during orthoPaEdic operations: The PERISCOPE trial.

Richards D., (2024), Bmj open

Current usage of explainer animations in trials: a survey of the UKCRC registered clinical trial units in the UK.

Barber VS. et al, (2024), Trials, 25

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.

Kawano-Dourado L. et al, (2024), Thorax

Use of oxygen-loaded nanobubbles to improve tissue oxygenation: Bone-relevant mechanisms of action and effects on osteoclast differentiation.

Knowles HJ. et al, (2024), Biomaterials, 305

Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.

Hayward G. et al, (2024), J infect

Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients

Standing JF. et al, (2024), Nature communications, 15

Time to speed up scientific deliveries in fibrotic interstitial lung disease: Innovative clinical trial design to improve patient care

RICHARDS D., (2024), Thorax

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial.

Png ME. et al, (2024), Br j gen pract

Single cell spatial analysis reveals inflammatory foci of immature neutrophil and CD8 T cells in COVID-19 lungs.

Weeratunga P. et al, (2023), Nat commun, 14

Optimising Psoriatic Arthritis Therapy with Immunological Methods to Increase Standard Evaluation: The protocol of an open-label multi-centre, parallel-group, two arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.

RICHARDS D., (2023), Bmj open

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease.

Gbinigie O. et al, (2023), Bmj open, 13

In vivo human keyhole limpet hemocyanin challenge in early phase drug development: A systematic review.

Drennan PG. et al, (2023), Clin transl sci, 16, 357 - 382

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.

Butler CC. et al, (2022), Lancet

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study

Richards D. et al, (2022), Orphanet journal of rare diseases, 17

In vivo human keyhole limpet haemocyanin challenge in early phase drug development: A systematic review

Drennan P. et al, (2022), Clinical and translational science

Load More